Richard Faris, PhD, RPh

The series concludes looking at the proposition that patients with rare and devastating disorders require and deserve a higher acuity of care and service that only an accredited rare pharmacy can deliver.

Challenges and impact of rare diseases are faced by pharmacy stakeholders.

The rarity of disease states coupled with novel medication mechanisms and high costs lead to complexities in accessing treatment and optimizing outcomes.